Fosaprepitant - USA

IPR decision: Apr. 20, 2020

AIA Review #	Filing Date	Institution Date	Petitioner	Patent	Respondent	Status
IPR2019-01446	08/01/2019	01/31/2020	Nevakar, Inc.	9,913,853	Cipla	Terminated-Dismissed

US 9,913,853 (Cipla Ltd.; Exp: 11/3/2036)

1. A liquid composition comprising fosaprepitant or a salt thereof and at least one liquid excipient, wherein after storage at 2-8.degree. C. for at least 1 month, aprepitant is present in an amount concentration of no more than 10%, wherein the composition is ready-to-use or ready-to-dilute.

17. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; b) at least one salt of ethylenediaminetetraacetic acid in an amount from 10-100 mg; c) albumin in an amount from 250 mg-100 g; and d) water in an amount from 3-300 ml.

20. A liquid pharmaceutical composition comprising: a) fosaprepitant dimeglumine in an amount from 50-250 mg; and b) at least one solubilizer in an amount from 1-5 ml.